Statements (13)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:chemicalFormula |
C27H28F3N5O3
|
| gptkbp:clinicalTrialPhase |
Phase 2
|
| gptkbp:developedBy |
gptkb:Pfizer
|
| https://www.w3.org/2000/01/rdf-schema#label |
PF-06882961
|
| gptkbp:intendedUse |
treatment of type 2 diabetes
|
| gptkbp:mechanismOfAction |
glucagon receptor antagonist
|
| gptkbp:molecularWeight |
527.54 g/mol
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:status |
investigational
|
| gptkbp:target |
gptkb:glucagon_receptor
|
| gptkbp:bfsParent |
gptkb:1805230-56-4
|
| gptkbp:bfsLayer |
8
|